Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hadassah Medical Organization |
---|---|
Information provided by: | Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT00149032 |
Allogeneic stem cell transplantation is the only effective treatment to patients resistant to conventional chemotherapy. Donor lymphocytes infusion (DLI) serve as a routine treatment of choice for patients relapsing following allogeneic stem cell transplantation. The present proposal is presented for introducing the use of immune rather than naive donor lymphocytes for patients with resistant relapse and resistant to DLI. DLI primed in-vitro against tumor cells of host origin or against host alloantigens presented by parental alloantigens in one way mixed lymphocytes culture can induce much more than potent graft-vs-leukemia and graft-vs-tumor effects, while down-regulating graft-vs-host disease (GVHD).
Condition | Intervention | Phase |
---|---|---|
Hematological Malignancy Neoplasm Metastasis |
Procedure: DLI sensitized against antigens expressed by the host. |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Treatment of Patients With Resistant Cancer/ Post Allogeneic Stem Cell Transplantation With Donor Lymphocytes Sensitized by Antigens Expressed by the Host |
Estimated Enrollment: | 50 |
Study Start Date: | August 2001 |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Israel | |
Hadassah Medical Organization | Recruiting |
Jerusalem, Israel, 91120 | |
Contact: Arik Tzukert, DMD +972-2-6777572 arik@hadassah.org.il | |
Contact: Hadas Lemberg, PhD +972-2-6777572 lhadas@hadassah.org.il | |
Principal Investigator: Shimon Slavin, MD |
Principal Investigator: | Shimon Slavin, MD | Hadassah Medical Organization |
Study ID Numbers: | 240801-HMO-CTIL |
Study First Received: | September 7, 2005 |
Last Updated: | May 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00149032 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Metastatic solid tumor |
Hematologic Neoplasms Hematologic Diseases Neoplasm Metastasis |
Neoplasms Neoplastic Processes Neoplasms by Site Pathologic Processes |